MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders
Imported from official source
Children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, can now be treated with Casgevy (exagamglogene autotemcel), following an extension of its UK authorisation by the MHRA.
This version
- Version
- 1 of 1
- Recorded
- October 30, 2026 10:00
- Change
- Initial
- Content hash
f045e49fa5993b2a6262768e6bc23077- All versions
- Revision history